232 related articles for article (PubMed ID: 12857561)
1. Rituximab therapy for follicular lymphoma: a comprehensive review of its efficacy as primary treatment, treatment for relapsed disease, re-treatment and maintenance.
Cohen Y; Solal-Céligny P; Polliack A
Haematologica; 2003 Jul; 88(7):811-23. PubMed ID: 12857561
[TBL] [Abstract][Full Text] [Related]
2. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ
Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686
[TBL] [Abstract][Full Text] [Related]
3. Update on front-line therapy for follicular lymphoma: chemo-immunotherapy with rituximab and survival.
Turturro F
Expert Rev Anticancer Ther; 2007 Jul; 7(7):959-65. PubMed ID: 17627454
[TBL] [Abstract][Full Text] [Related]
4. Impact of rituximab and/or high-dose therapy with autotransplant at time of relapse in patients with follicular lymphoma: a GELA study.
Sebban C; Brice P; Delarue R; Haioun C; Souleau B; Mounier N; Brousse N; Feugier P; Tilly H; Solal-Céligny P; Coiffier B
J Clin Oncol; 2008 Jul; 26(21):3614-20. PubMed ID: 18559872
[TBL] [Abstract][Full Text] [Related]
5. Indolent lymphomas: current and emerging treatment approaches.
Maloney D; Kahl BS; Dreyling M
Clin Adv Hematol Oncol; 2006 Sep; 4(9 Suppl 20):1-10; quiz 11-2. PubMed ID: 17139243
[TBL] [Abstract][Full Text] [Related]
6. Effect of prior rituximab on high-dose therapy and autologous stem cell transplantation in follicular lymphoma.
Kang TY; Rybicki LA; Bolwell BJ; Thakkar SG; Brown S; Dean R; Sekeres MA; Advani A; Sobecks R; Kalaycio M; Pohlman B; Sweetenham JW
Bone Marrow Transplant; 2007 Nov; 40(10):973-8. PubMed ID: 17873917
[TBL] [Abstract][Full Text] [Related]
7. Optimizing the treatment of patients with rituximab-pretreated recurrent indolent non-Hodgkin lymphoma.
Leonard JP; Gregory SA; Maloney DG; Vose JM; Younes A; Zelenetz AD
Clin Adv Hematol Oncol; 2008 Jun; 6(6):437-45. PubMed ID: 18567989
[TBL] [Abstract][Full Text] [Related]
8. The therapeutic use of rituximab in non-Hodgkin's lymphoma.
Marcus R; Hagenbeek A
Eur J Haematol Suppl; 2007 Jan; (67):5-14. PubMed ID: 17206982
[TBL] [Abstract][Full Text] [Related]
9. Follicular lymphoma: time for a re-think?
Gandhi MK; Marcus RE
Blood Rev; 2005 May; 19(3):165-78. PubMed ID: 15748964
[TBL] [Abstract][Full Text] [Related]
10. Fludarabine plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as front-line treatment for patients with follicular lymphoma.
Zinzani PL; Pulsoni A; Perrotti A; Soverini S; Zaja F; De Renzo A; Storti S; Lauta VM; Guardigni L; Gentilini P; Tucci A; Molinari AL; Gobbi M; Falini B; Fattori PP; Ciccone F; Alinari L; Martelli M; Pileri S; Tura S; Baccarani M
J Clin Oncol; 2004 Jul; 22(13):2654-61. PubMed ID: 15159414
[TBL] [Abstract][Full Text] [Related]
11. Rituximab and its role as maintenance therapy in non-Hodgkin lymphoma.
Collins-Burow B; Santos ES
Expert Rev Anticancer Ther; 2007 Mar; 7(3):257-73. PubMed ID: 17338647
[TBL] [Abstract][Full Text] [Related]
12. Maintenance therapy for low-grade lymphomas: has the time come?
Cartron G; Solal-Céligny P
Curr Opin Oncol; 2007 Sep; 19(5):425-32. PubMed ID: 17762565
[TBL] [Abstract][Full Text] [Related]
13. Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin's lymphoma--a randomized phase II trial of the Minnie Pearl Cancer Research Network.
Hainsworth JD; Litchy S; Shaffer DW; Lackey VL; Grimaldi M; Greco FA
J Clin Oncol; 2005 Feb; 23(6):1088-95. PubMed ID: 15657401
[TBL] [Abstract][Full Text] [Related]
14. [Efficacy of rituximab-containing regimens on indolent B-cell lymphoma--a report of 34 cases].
Xia ZJ; Wang FH; Huang HQ; Luo HY; Li YH; Lin TY; Jiang WQ; Guan ZZ
Ai Zheng; 2006 Apr; 25(4):490-4. PubMed ID: 16613687
[TBL] [Abstract][Full Text] [Related]
15. Immunotherapy in mantle cell lymphoma: anti-CD20-based therapy and beyond.
Zhou Y; Zhang L; Romaguera J; Delasalle K; Han X; Du X; Kwak L; Yi Q; Wang M
Am J Hematol; 2008 Feb; 83(2):144-9. PubMed ID: 17722077
[TBL] [Abstract][Full Text] [Related]
16. Current management of follicular lymphomas.
Hiddemann W; Buske C; Dreyling M; Weigert O; Lenz G; Unterhalt M
Br J Haematol; 2007 Jan; 136(2):191-202. PubMed ID: 17073892
[TBL] [Abstract][Full Text] [Related]
17. Current status and perspective of antibody therapy in follicular lymphoma.
Buske C; Weigert O; Dreyling M; Unterhalt M; Hiddemann W
Haematologica; 2006 Jan; 91(1):104-12. PubMed ID: 16434378
[TBL] [Abstract][Full Text] [Related]
18. Current controversies in follicular lymphoma.
Aurora V; Winter JN
Blood Rev; 2006 Jul; 20(4):179-200. PubMed ID: 16410034
[TBL] [Abstract][Full Text] [Related]
19. Durable complete responses from therapy with combined epratuzumab and rituximab: final results from an international multicenter, phase 2 study in recurrent, indolent, non-Hodgkin lymphoma.
Leonard JP; Schuster SJ; Emmanouilides C; Couture F; Teoh N; Wegener WA; Coleman M; Goldenberg DM
Cancer; 2008 Nov; 113(10):2714-23. PubMed ID: 18853418
[TBL] [Abstract][Full Text] [Related]
20. One single dose of rituximab added to a standard regimen of CHOP in primary treatment of follicular lymphoma appears to result in a high clearance rate from circulating bcl-2/IgH positive cells: Is the end of molecular monitoring near?
Schmitt C; Grundt A; Buchholtz C; Scheuer L; Benner A; Hensel M; Ho AD; Leo E
Leuk Res; 2006 Dec; 30(12):1563-8. PubMed ID: 16530831
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
